What is the recommended intravenous antibiotic regimen for cellulitis, including coverage for methicillin‑susceptible Staphylococcus aureus, streptococci, and options for MRSA risk or beta‑lactam allergy?

Intravenous Antibiotic Treatment for Cellulitis

For hospitalized patients with complicated cellulitis requiring IV antibiotics, start with IV vancomycin (15 mg/kg every 12 hours) as first-line empirical therapy for MRSA coverage, or use cefazolin (0.5-1 g every 8 hours IV) for nonpurulent cellulitis in patients without MRSA risk factors, switching to MRSA-active therapy only if there is no clinical response within 48-72 hours 1, 2.

Clinical Decision Algorithm

Step 1: Determine if IV antibiotics are needed

Hospitalization and IV therapy are indicated for:

• Severe or extensive disease involving multiple sites
• Rapid progression with systemic signs (fever, hypotension, tachycardia)
• Immunosuppression or significant comorbidities
• Failed outpatient oral therapy
• Inability to tolerate oral medications

Step 2: Classify the cellulitis type

Nonpurulent cellulitis (96.5% of cases):

• No purulent drainage or exudate
• No drainable abscess
• Typical presentation: expanding erythema, warmth, tenderness, swelling
• Primary pathogens: β-hemolytic streptococci (Group A Streptococcus), methicillin-sensitive S. aureus

Purulent cellulitis (rare):

• Associated with purulent drainage without drainable abscess
• Higher likelihood of MRSA involvement

Step 3: Select empirical IV antibiotic regimen

For nonpurulent cellulitis (most common):

• First-line: IV cefazolin 0.5-1 g every 8 hours 1
• Alternative: IV oxacillin or nafcillin 2 g every 6 hours 3
• These β-lactams cover streptococci and methicillin-sensitive S. aureus (80-90% of community-acquired pathogens remain susceptible) 4
• Add MRSA coverage only if: No clinical improvement after 48-72 hours, or patient has systemic toxicity at presentation 1

For complicated SSTI or when MRSA coverage is needed:

Primary options (all A-I evidence):

• IV vancomycin: 15 mg/kg every 12 hours (most commonly used) 1, 2
• IV linezolid: 600 mg every 12 hours 1, 2
• IV daptomycin: 4 mg/kg once daily 1, 2
• IV telavancin: 10 mg/kg once daily 1, 2

Secondary option:

• IV clindamycin: 600 mg every 8 hours (A-III evidence; use only if local clindamycin resistance <10%) 1

Step 4: Special considerations for β-lactam allergy

If true penicillin/cephalosporin allergy and MRSA coverage needed:

• Use vancomycin, linezolid, daptomycin, or telavancin as above
• Avoid clindamycin unless local resistance rates are documented <10%

If β-lactam allergy but low MRSA risk:

• Consider IV fluoroquinolone (levofloxacin 750 mg every 24 hours) plus metronidazole for polymicrobial coverage 3

Step 5: Duration and transition strategy

• Treatment duration: 7-14 days total, individualized based on clinical response 1, 2, 1
• Transition to oral: Once clinically improving (defervescence, decreased erythema/swelling), typically after 2-4 days of IV therapy
• Oral step-down options:
  • For streptococcal coverage: cephalexin 500 mg every 6 hours
  • For MRSA coverage: clindamycin 300-450 mg every 8 hours, TMP-SMX 1-2 DS tablets twice daily, or doxycycline 100 mg twice daily

Critical Pitfalls to Avoid

1. Overuse of MRSA-active therapy: The majority of nonpurulent cellulitis is caused by streptococci, not S. aureus. Starting with vancomycin for all cellulitis cases contributes to resistance and unnecessary cost. Begin with cefazolin unless specific MRSA risk factors exist 1, 5.

2. Misdiagnosis of cellulitis: Bilateral lower extremity "cellulitis" is almost never infectious—consider venous stasis dermatitis, contact dermatitis, or deep venous thrombosis instead 6, 5. True bilateral cellulitis is exceedingly rare.

3. Treating abscesses with antibiotics alone: If imaging (point-of-care ultrasound) reveals an abscess, incision and drainage is the primary treatment. Antibiotics are adjunctive 1, 2, 6.

4. Ignoring local resistance patterns: Clindamycin resistance in S. aureus exceeds 10% in many regions. Verify local antibiograms before using clindamycin empirically 1.

5. Inadequate vancomycin dosing: Vancomycin requires weight-based dosing (15 mg/kg/dose) with trough monitoring to achieve therapeutic levels, particularly for serious infections 1.

Pediatric Modifications

For hospitalized children with complicated cellulitis:

• First-line: IV vancomycin (dose per pediatric protocols) 1, 2, 1
• Alternative (if stable, no bacteremia): IV clindamycin 10-13 mg/kg/dose every 6-8 hours (40 mg/kg/day total) if local resistance <10% 1
• Alternative: Linezolid 10 mg/kg/dose every 8 hours for children <12 years; 600 mg twice daily for ≥12 years 1, 2
• Avoid tetracyclines in children <8 years of age 1

Evidence Quality Note

These recommendations are based on IDSA guidelines from 2011 1, 2 and 2014 3, which remain the most authoritative sources despite their age. The core principles—β-lactams for nonpurulent cellulitis, MRSA coverage for purulent or treatment-failure cases—are supported by consistent clinical practice patterns and microbiologic data showing streptococci as the predominant pathogen in typical cellulitis 4, 5.